Home » NEUROCRINE POSTS THIRD-QUARTER PROFIT
NEUROCRINE POSTS THIRD-QUARTER PROFIT
Neurocrine Biosciences Inc., a developer of treatments for nervous and immune system disorders, posted a third-quarter profit Monday, as a payment from product partner Pfizer Inc. boosted revenue. The company also said it now expects a smaller loss for the year. Neurocrine recorded a profit of $26.2 million, or 68 cents per share, compared with a year-ago loss of $1.65 million, or 5 cents a share.
MSN Money (http://news.moneycentral.msn.com/provider/providerarticle.asp?feed=AP&Date=20051024&ID=5217746)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May